» Articles » PMID: 38852121

Management of ROS and Regulatory Cell Death in Myocardial Ischemia-Reperfusion Injury

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2024 Jun 9
PMID 38852121
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial ischemia-reperfusion injury (MIRI) is fatal to patients, leading to cardiomyocyte death and myocardial remodeling. Reactive oxygen species (ROS) and oxidative stress play important roles in MIRI. There is a complex crosstalk between ROS and regulatory cell deaths (RCD) in cardiomyocytes, such as apoptosis, pyroptosis, autophagy, and ferroptosis. ROS is a double-edged sword. A reasonable level of ROS maintains the normal physiological activity of myocardial cells. However, during myocardial ischemia-reperfusion, excessive ROS generation accelerates myocardial damage through a variety of biological pathways. ROS regulates cardiomyocyte RCD through various molecular mechanisms. Targeting the removal of excess ROS has been considered an effective way to reverse myocardial damage. Many studies have applied antioxidant drugs or new advanced materials to reduce ROS levels to alleviate MIRI. Although the road from laboratory to clinic has been difficult, many scholars still persevere. This article reviews the molecular mechanisms of ROS inhibition to regulate cardiomyocyte RCD, with a view to providing new insights into prevention and treatment strategies for MIRI.

Citing Articles

Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.

Zhu K, Wang K, Zhang R, Zhu Z, Wang W, Yang B J Nanobiotechnology. 2025; 23(1):112.

PMID: 39955554 PMC: 11829476. DOI: 10.1186/s12951-025-03197-1.


Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury.

Zhang Y, Jiang M, Wang T Front Bioeng Biotechnol. 2024; 12:1469393.

PMID: 39286345 PMC: 11402825. DOI: 10.3389/fbioe.2024.1469393.

References
1.
Haubner B, Schuetz T, Penninger J . A reproducible protocol for neonatal ischemic injury and cardiac regeneration in neonatal mice. Basic Res Cardiol. 2016; 111(6):64. PMC: 5035663. DOI: 10.1007/s00395-016-0580-3. View

2.
Poh B, Liew L, Soh Y, Lai R, Lim S, Ho Y . MSC-Derived Small Extracellular Vesicles Exert Cardioprotective Effect Through Reducing VLCFAs and Apoptosis in Human Cardiac Organoid IRI Model. Stem Cells. 2024; 42(5):416-429. DOI: 10.1093/stmcls/sxae015. View

3.
Fox C, Evans J, Larson M, Kannel W, Levy D . Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation. 2004; 110(5):522-7. DOI: 10.1161/01.CIR.0000136993.34344.41. View

4.
Wijeysundera H, Machado M, Farahati F, Wang X, Witteman W, van der Velde G . Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010; 303(18):1841-7. DOI: 10.1001/jama.2010.580. View

5.
Olier I, Sirker A, Hildick-Smith D, Kinnaird T, Ludman P, de Belder M . Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018; 104(20):1683-1690. DOI: 10.1136/heartjnl-2017-312366. View